37 related articles for article (PubMed ID: 12898523)
1. Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis.
Ohki R; Kawase T; Ohta T; Ichikawa H; Taya Y
Cancer Sci; 2007 Feb; 98(2):189-200. PubMed ID: 17233836
[TBL] [Abstract][Full Text] [Related]
2. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth.
Zhang Y; Zhang C; Li J; Jiang M; Guo S; Yang G; Zhang L; Wang F; Yi S; Wang J; Fu Y; Zhang Y
Cell Commun Signal; 2022 Jun; 20(1):93. PubMed ID: 35715817
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
5. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
[TBL] [Abstract][Full Text] [Related]
7. Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.
Węsierska-Gądek J; Walzi E; Dolečkova I; Schmid G
Cancer Microenviron; 2009 Sep; 2(Suppl 1):215-25. PubMed ID: 19731086
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribosyl)ation in mammalian ageing.
Beneke S; Bürkle A
Nucleic Acids Res; 2007; 35(22):7456-65. PubMed ID: 17913748
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora-B kinase activity by poly(ADP-ribosyl)ation in response to DNA damage.
Monaco L; Kolthur-Seetharam U; Loury R; Murcia JM; de Murcia G; Sassone-Corsi P
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14244-8. PubMed ID: 16179389
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury.
Strosznajder RP; Jesko H; Zambrzycka A
Mol Neurobiol; 2005; 31(1-3):149-67. PubMed ID: 15953818
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635
[TBL] [Abstract][Full Text] [Related]
12. Signaling to p53: breaking the posttranslational modification code.
Appella E; Anderson CW
Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
[TBL] [Abstract][Full Text] [Related]
13. Physiological ageing: role of p53 and PARP-1 tumor suppressors in the regulation of terminal senescence.
Wesierska-Gadek J; Ranftler C; Schmid G
J Physiol Pharmacol; 2005 Mar; 56 Suppl 2():77-88. PubMed ID: 16077192
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1.
Wesierska-Gadek J; Wojciechowski J; Schmid G
J Cell Biochem; 2003 Aug; 89(6):1260-84. PubMed ID: 12898523
[TBL] [Abstract][Full Text] [Related]
15. Advantage of a baculovirus expression system for protein-protein interaction studies. Involvement of posttranslational phosphorylation in the interaction between wt p53 protein and poly(ADP-ribose) polymerase-1.
Schmid G; Wojciechowski J; Wesierska-Gadek J
Acta Biochim Pol; 2005; 52(3):713-9. PubMed ID: 16082409
[TBL] [Abstract][Full Text] [Related]
16. Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1.
Wesierska-Gadek J; Wojciechowski J; Schmid G
J Cell Biochem; 2003 May; 89(2):220-32. PubMed ID: 12704785
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
